Curriculum Vitae of Dr Michelle Viljoen

Size: px

Start display at page:

Download "Curriculum Vitae of Dr Michelle Viljoen"

Rhoda Reed
7 years ago
Views:

1 Curriculum Vitae of Dr Michelle Viljoen 1. General information Title, name and surname: Dr Michelle Viljoen Date of birth: 1970/08/29 Citizenship: RSA Professional registrations: SAPC Contact details Organisation where based: North-West University (NWU) Faculty or School: Faculty Health Sciences: School of Pharmacy Work telephone number: +27 (0) Work fax number: +27 (0) Cell phone number: +27 (0) address: Website address: Work postal address: Private Bag X6001, Potchefstroom South Africa, 2520 Work physical address: North-West University (NWU) Potchefstroom Campus 11 Hoffman street Building G16, Room 121A Potchefstroom, Qualifications (Start with most recent) PhD Pharmacology North-West University Year obtained: 2011 M.Sc Pharmacology Cum Laude North-West University (PU for CHE) Year obtained: 1996 B.Pharm Pharmacy Cum Laude North-West University (PU for CHE) Year obtained: 1993

2 4. Employment history (From current backwards. Not more than five) Position: Organisation Appointed from to: Senior Lecturer: School of North-West University (NWU), March Current Pharmacy Potchefstroom Campus Temporary Lecturer Potchefstroom University for Jan 2002 Feb 2003 Christian Higher Education (PU for CHE) Part time Lecturer Pharmacology for Nursing students RAU University of Johanneburg (UJ) May Dec 2007 Full time pharmacist (Wards; Outpatients; Laminar Flow; Primary Health Care Clinics). Health and Training Consultant. Session locum at Potchefstroom Provincial Hospital Part time Locum Pharmacist Potchefstroom Provincial Hospital June 2001 Dec Univata CC, Potchefstroom March 2000 May 2001 Eland Pharmacy; Miederpark Pharmacy; Mooirivier Pharmacy - Potchefstroom Research expertise Scientific domain: Pharmacology Main research field: Pharmacogenetics, metabolism & pharmacokinetics of antiretroviral drugs (ARV s) Fields of specialisation: Pharmacogenetics, metabolism & pharmacokinetics of antiretroviral drugs (ARV s) NRF rating and year rated: - 6. Publications (List publications over the last three years) International publications: Viljoen, M. Loots, DT. Rheeders, M. Gous, HS. Routine drug level monitoring of first line ARV regimen in a South African paediatric HIV roll-out clinic. The Canadian Journal of Clinical Pharmacology, (3):e753. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M. Efavirenz Plasma Concentrations at 1, 3 and 6 Months Post Antiretroviral Therapy Initiation in HIV-1 Infected South African Children. Aids Research and Human Retroviruses, (6): Theron A, Cromarty D, Rheeders M, Viljoen M. Determination of salivary efavirenz by liquid chromatography coupled with tandem mass spectrometry. Chromatography B, : du Plooy M, Viljoen M, Rheeders M. Evidence for timedependent interactions between ritonavir and lopinavir / ritonavir (LPV/r) plasma levels following P-gp inhibition in Sprague-Dawley rats. Biological and Pharmaceutical Bulletin, 2011, 34 (1):66-70.

3 National publications: Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. European Journal of Clinical Pharmacology, 2012, 68: DOI /s Viljoen, M. Meyer, CL. Lubbe, MS. The prevalence of sideeffects: Ciprofloxacin 500 mg single dose prophylaxis against Neisseria Meningitidis outbreak in Potchefstroom during July Health SA Gesondheid: (3): Papers delivered (List papers over the last three years) International papers: Viljoen, M. Loots, DT. Rheeders, M. Gous, HS. Routine drug level monitoring of first line ARV regimen in a South African paediatric HIV roll-out clinic. IX th World Conference on Clinical Pharmacology and Therapeutics, 27July-1 Aug. 2008, Quebec, Canada. (Poster) Viljoen, M. Gous, H. Kruger, H.S. Riddick, A. & Rheeders, M. Efavirenz plasma concentrations at 1,3 and 6 months post antiretroviral treatment in HIV-1 infected South African children. I st International Workshop HIV Pediatrics, July 2009, Cape Town, South Africa. (Poster) Kruger, H.S. Viljoen, M. Gous, Haupt, C. Improvement in nutritional status of HIV-infected children after starting highly active antiretroviral therapy. I st International Workshop HIV Pediatrics, July 2009, Cape Town, South Africa. (Poster) Theron, A. Viljoen, M. Rheeders. A pilot study to investigate the predictability of efavirenz plasma levels in HIV-1 infected South African children. 5 th International Conference on Pharmaceutical and Pharmacological Sciences (ICPPS), September 2009, North-West University, Potchefstroom Campus (Podium). Kruger, HS, Viljoen, M. Haupt, C, Meyers, TM. Improved body composition of HIV-1 infected stunted children after one year of antiretroviral therapy. IUNS 5-8 October 2009, Bangkok, Thailand. (Poster) Viljoen M, Theron A, Cromarty D, Rheeders M, Jansen van Rensburg PJ, Malan L. Determination of efavirenz in human saliva by high performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). 2 ND International Workshop on HIV Pediatrics, July 2010, Vienna, Austria. (Poster) Viljoen M, Dandara C, Rheeders M, Conradie KR, Kruger HS, Meyers TM, Gous H. Prevalence of CYP2B6-516G>T polymorphism in black South African HIV-infected children on efavirenz based antiretroviral therapy. 16 TH World Congress of Basic and Clinical Pharmacology, July 2010, Copenhagen, Denmark. (Poster) Rheeders M, Viljoen M, Theron M, Meyers TM. Saliva as a

4 National papers: non-invasive alternative to plasma efavirenz. 16 TH World Congress of Basic and Clinical Pharmacology, July 2010, Copenhagen, Denmark. (Poster) Viljoen M, Rheeders M, Meyers TM, Gous H, Dandara C, Kruger HS,. Efavirenz plasma concentrations during 24 months follow-up post-art in HIV-infected South African children. 3 rd International Workshop on HIV Pediatrics, July 2011, Rome, Italy. (Oral Poster presentation). Viljoen M, Rheeders M. The prevalence and impact of CYP2B6 516 G>T polymorphism in black South African HIVinfected children on efavirenz based antiretoviral therapy. Pharmacogenetics Mini Symposium, 1-2 Dec 2011, Human Genetics, Pharmacogenetics and Cancer Research group, UCT, Cape Town. (Oral presentation) Kruger HS, Viljoen M, Haupt C, Meyers TM. Improved growth and body composition on HIV-infected African children after two years of antiretroviral therapy. 1 st International Conference on Nutrition and Growth, 28 Feb 4 March 2012, Paris, France. Reay R, Viljoen M, Rheeders M, Dandara C, Swart M, Meyers TM. CYP 2B6(c.516G>T) and CYP2B6*6 polymorphisms are indicative predictors of efavirenz plasma concentrations in black South African HIV-infected children. 5 th All African Congress on Basic & Clinical Pharmacology, July 2012, Accra, Ghana. (Poster presentation) Viljoen M. Rheeders M, Meyers TM, Gous H. Dandara C. Kruger HS. Two-year treatment outcomes of efavirenz-based first line regimen among South African children genotyped for CYP2B6 516 G>T. 4 th International Workshop on HIV Pediatrics, July 2012 & XIX International AIDS conference (AIDS2012), July 2012, Washington DC, USA. Viljoen, M. Meyer, CL. Lubbe, MS. The prevalence of sideeffects: Ciprofloxacin 500 mg single dose prophylaxis against Neisseria Meningitidis outbreak in Potchefstroom during July th Annual Congress South African Pharmacological Society, October 2004 (Poster). Du Plooy M., Rheeders, M. & Viljoen, M Investigating the effect of P-glycoprotein (P-gp) inhibition in blood levels on the metabolism of selective antiretroviral drugs, in Sprague- Dawley rats. South African Society for Basic and Clinical Pharmacology, Rhodes University, Grahamstown, South Africa, 5-8 October (Podium) Viljoen M, Rheeders M,. The prevalence and impact of CYP2B6 516 G>T polymorphism in black South African HIVinfected children on efavirenz based antiretoviral therapy. Pharmacogenetics Mini Symposium, 1-2 Dec 2011, Human Genetics, Pharmacogenetics and Cancer Research group, UCT, Cape Town. (Oral presentation) Engelbrecht L, Viljoen FP, Viljoen M, Brand L. A specific and sensitive method for the determination of levetiracetam in human plasma/serum in patients with epilepsy. Laboratory Medicine Congress 2011, 31 Aug 4 Sep 2011, Sandton Convention Centre. (Poster presentation).

Work postal address: Northwest University, Mechanical Engineering, Potchefstroom Work physical address: Tweelingspruit, Biesiesvlei, 2755

Work postal address: Northwest University, Mechanical Engineering, Potchefstroom Work physical address: Tweelingspruit, Biesiesvlei, 2755 Curriculum Vitae of Dr. C.B. Nel 1. General information Title, name and surname: Dr. Carl Benjamin Nel Date of birth: 8 February 1963 Citizenship: RSA Professional registrations: Pr. Tech. (Eng.) 2. Contact